Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01447914 · OUTCOME

Cycles of Tivantinib Treatment Administered

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma · Source last updated 2019-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
number of treatment cycles
Interval / dispersion
Full Range
Time frame
From start of participant treatment to completion or disease progression; assessed up to 16 months

What was measured

Number of treatment cycles completed by study participants.

Analysis population: No participants responded to the therapy and no analyses were done

Groups in this outcome

Tivantinib Treatment

Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Tivantinib Treatment16

Reported measurements

Source class 1
Values in number of treatment cycles · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Tivantinib Treatment4Not reported115Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        15
        value
        4
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    units
    Participants
description
Number of treatment cycles completed by study participants.
dispersion Type
Full Range
groups
  1. description
    Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)
    id
    OG000
    title
    Tivantinib Treatment
param Type
MEAN
population Description
No participants responded to the therapy and no analyses were done
reporting Status
POSTED
time Frame
From start of participant treatment to completion or disease progression; assessed up to 16 months
title
Cycles of Tivantinib Treatment Administered
type
POST_HOC
unit Of Measure
number of treatment cycles

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice